Drug Profile


Alternative Names: Amigal; AT 1001; Galafold; GR181413A; HGT-3310; Migalastat hydrochloride

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amicus Therapeutics
  • Developer Amicus Therapeutics; GlaxoSmithKline
  • Class Imino sugars; Pharmacological chaperones; Piperidines; Small molecules
  • Mechanism of Action Alpha-galactosidase stimulants; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fabry's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fabry's disease

Most Recent Events

  • 19 Sep 2017 Migalastat receives Fast Track designation for Fabry's disease [PO,Capsule] (Monotherapy) in USA
  • 14 Sep 2017 Registered for Fabry's disease (Monotherapy) in Canada (PO)
  • 15 Aug 2017 Registered for Fabry's disease (Monotherapy) in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top